36th Annual J.P. Morgan Healthcare Conference

Hanmi Pharmaceutical Co., Ltd.

Se Chang Kwon
President & CEO
Forward-Looking Statements

This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Hanmi Pharmaceutical Company. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities.
Who We Are

Hanmi is a leading R&D oriented company with fully integrated value chains in Korea and China.

Hanmi Science

- Hanmi Pharm
- Beijing Hanmi
- Hanmi Fine Chem.

- Hanmi IT
- Hanmi Medicare
- Online Pharm
- Hanmi Japan
- Hanmi Europe
- Hanmi China
- JVM

(Automated Drug Packaging System Company)

Acquisition in June 2016
Our Key Businesses

KOREA
• Headquarters (Seoul)
• 5 R&D centers
• 3 Manufacturing sites
• Innovative drug development
  - LAPSCOVERY Platform
  - Targeted NCE Discovery

GLOBAL
• Partnerships worth $6B to date
• Our Valued Global Partners

CHINA
• Beijing Hanmi
• Manufacturing & local sales networks
• Novel research activity
  - PENTAMBODY Platform
We Value Our R&D

✓ Strong focus on R&D with over +550 experts (Ph.D 64)

✓ We continue to invest nearly 20% of revenue on R&D

Total 2,195 Employees

25% R&D Staffs

75%

Sales (mn USD)

2015*  711
2016  761
2017E  804

R&D (% to sales)

11

18%

18%

14%

*2015 sales exclude upfront & milestone payments
**2017E sales and R&D spending are annualized
***Exchange rate (1USD:KRW): 1131.49 ('15); 1,160.50 ('16); 1,134.23 ('17)
Hanmi R&D Network

Hanmi R&D Center

NCE & NBE Drug Discovery
Clinical Translational Research
Dongtan, Korea

Seoul R&D Center (HQ)
eR&D, Clinical & Regulatory
Songpa-gu, Korea

Hanmi Fine Chemical
Mass Production Research of APIs
Shihwa, Korea

Beijing Hanmi R&D Center

NCE & Bi-specific Antibody
Equipped with primate facility
Beijing China

Formulation Research Center
Formulation, DDS Research
Paltan, Korea

Bio Process Development Center
Bio Process Research
Pyeongtaek, Korea

* NCE (New Chemical Entity) / NBE (New Biological Entity)
Hanmi Manufacturing Capacity

### Finished Product Plant
- 4th generation SMART plant
- Highly-automated
- Annual production capacity: max. 12 bil. tablets/capsules
- CMO business expansion

### API Plant
- Leader for 30+ years in APIs
- Inspected & Approved by US/EU/JP authorities
- High-quality API export

### Bio Plant

#### Expanded production Capa. by 10-fold
- for global commercialization

**1Q 2017**
- Microorganism Production Lines:
  - 1,000L x 2 lines
  - 300L x 4 lines
  - 5 DS, 3 DP

**1Q 2018**
- Microorganism Production Lines:
  - 10,000L x 2 lines
  - 1,000L x 2 lines
  - 300L x 4 lines
  - 5+2 DS, 3 DP

NEW Bio Plant
Innovating our way FORWARD

Novel Therapeutics

2000~2014
LAPSCOVERY
Proprietary long-acting protein/peptide discovery platform

Targeted Oncology & NCE

2015~2017
Landmark out-licensing deals to MNCs

Strategically Evolving

Innovation in core therapeutic areas
Oncology, Autoimmune, Metabolic, Rare diseases

Clinical Translational Research

New Platform: Pentambody
Proprietary bispecific antibody program developed by BJ Hanmi as next generation platform
RESEARCH UPDATE
Areas of Focus in Innovative R&D

**Metabolic Diseases**
- LAPS Triple Agonist (GLP-1/GIP/GCG)
- LAPS Insulin

**Oncology**
- FLT3 Inhibitor Olita® (Olmustinib)
- Poziotinib

**Rare Diseases**
- LAPS GLP-2 Analog
- LAPS ERT*

**Immuno-therapy**
- PD-L1/PD-1 Bispecific Ab

* ERT (Enzyme Replacement Therapy)
## Innovative R&D Pipeline (Jan 2018)

<table>
<thead>
<tr>
<th>Pre-Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diabetes/Obesity /NASH</strong></td>
<td><strong>Diabetes</strong></td>
<td><strong>Diabetes</strong></td>
<td><strong>Diabetes</strong></td>
</tr>
<tr>
<td>HM14220 (LAPS Insulin Combo)</td>
<td>HM15211 (LAPS Triple Agonist)</td>
<td>Efpeglenatide (LAPS Exd4 Analog)</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>NASH/Obesity</td>
<td>Diabetes</td>
<td></td>
</tr>
<tr>
<td>HM12480 (LAPS Insulin148)</td>
<td>HM12255A (LAPS GLP/GCG)</td>
<td>Diabetes</td>
<td>Efpeglenatide (LAPS Exd4 Analog)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Diabetes/Obesity</td>
<td>Diabetes</td>
<td></td>
</tr>
<tr>
<td><strong>Oncology</strong></td>
<td><strong>Diabetes</strong></td>
<td><strong>Diabetes</strong></td>
<td><strong>Diabetes</strong></td>
</tr>
<tr>
<td>HM43239 (FLT3 Inhibitor) AML</td>
<td>HM95573 (Pan-RAF Inhibitor) Solid tumor</td>
<td>Oravolite (Lapatinib Inhibitor) Solid tumor</td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes</strong></td>
<td><strong>Diabetes</strong></td>
<td><strong>Diabetes</strong></td>
<td><strong>Diabetes</strong></td>
</tr>
<tr>
<td>HM21001 (GMB Stem Cell Therapy) Glioblastoma</td>
<td>Oratecan™ (Irinotecan+HM21014A) Solid tumor</td>
<td>Oravolite (Lapatinib Inhibitor) Solid tumor</td>
<td></td>
</tr>
<tr>
<td>BH2950 (PD-1/TAA BsAb) Targeted immuno-oncology</td>
<td>KX2-391 (Src/Tubulin Inhibitor) Solid tumor</td>
<td>Oravolite (Lapatinib Inhibitor) Solid tumor</td>
<td></td>
</tr>
<tr>
<td>BH2951 (PD-1/PD-L1 BsAb) Targeted immuno-oncology</td>
<td>BH2954 (PD-1 BsAb) Targeted immuno-oncology</td>
<td>BH2954 (PD-1 BsAb) Targeted immuno-oncology</td>
<td></td>
</tr>
<tr>
<td><strong>Autoimmune</strong></td>
<td><strong>Autoimmune diseases</strong></td>
<td><strong>Autoimmune diseases</strong></td>
<td><strong>Autoimmune diseases</strong></td>
</tr>
<tr>
<td>HM15136 (LAPS GCG Analog) Congenital hyperinsulinism</td>
<td>HM71224 (BTK Inhibitor) Autoimmune diseases</td>
<td><strong>Autoimmune diseases</strong></td>
<td></td>
</tr>
<tr>
<td>Rare Diseases</td>
<td><strong>Autoimmune diseases</strong></td>
<td><strong>Autoimmune diseases</strong></td>
<td><strong>Autoimmune diseases</strong></td>
</tr>
<tr>
<td>HM15450 (LAPS ASB) Mucopolysaccharidosis</td>
<td>HM15910 (LAPS GLP-2 Analog) Short bowel syndrome</td>
<td><strong>Autoimmune diseases</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td><strong>Open to Partnering Discussions</strong></td>
<td><strong>Open to Partnering Discussions</strong></td>
<td><strong>Open to Partnering Discussions</strong></td>
</tr>
<tr>
<td><strong>Beijing Hamni</strong> 1) P3 in South America &amp; Taiwan 2) Launched in Korea 3) Tumor Associated Antigen</td>
<td><strong>Beijing Hamni</strong> 1) P3 in South America &amp; Taiwan 2) Launched in Korea 3) Tumor Associated Antigen</td>
<td><strong>Beijing Hamni</strong> 1) P3 in South America &amp; Taiwan 2) Launched in Korea 3) Tumor Associated Antigen</td>
<td><strong>Beijing Hamni</strong> 1) P3 in South America &amp; Taiwan 2) Launched in Korea 3) Tumor Associated Antigen</td>
</tr>
</tbody>
</table>
**Key Features**

- **High glucagon activity for liver targeting and NASH treatment**
- **Improved lipid profile and anti-inflammatory effect by GIP activity**
- **Multiple mechanisms of action accompanied with ‘fibrosis resolution’**
- **P1 trial filed in Dec. 2017**
Rare Disease: LAPSERT Program / Peptide for Rare Disease

LAPS offers commercially relevant differentiation

Key Features of LAPSERT Program

- Address key unmet needs via increased drug distribution
- Weekly IV infusion to Monthly SC injection reducing treatment burden

Key Features of LAPS-Peptide for Rare Diseases

- Long-acting drug in ready-to-inject, soluble formation
- LAPS-GCG36 reverses insulin induced chronic hypoglycemia
- LAPS-GLP-2 shows potent intestinotrophic activity

![Bar graph showing villus height comparison](image)
Oncology: FLT3 Inhibitor Program (HM43239) for AML

Next generation FLT3 Inhibitor overcoming resistance
via differentiated potency against TKD & acquired mutations, LSCs, and other activating pathways

Key Features

- Orally available, reversible Type I RTK inhibitor
- Active against wide range of FLT3 mutations in AML
- Potential for inhibiting:
  - Leukemic Stem Cells (LSCs)
  - Alternative activating signaling kinase (e.g., SYK, JAK)
Novel Pan-HER tyrosine kinase inhibitor

High unmet need for EGFR exon 20 mutation

Key Features

- **Small, flexible, halogenated quinazoline based TKI**

- **Significant antitumor activity in EGFR exon 20 mutant NSCLC patients; preliminary data showing a PR of 73% (MD Anderson Cancer Center sponsored trial)**

- **Multicenter phase 2 trial initiated in the US in 4Q 2017 (both EGFR and HER2 Exon 20 insertion-mutant NSCLC)**

† Preliminary data presented at IASLC 2017 by MD Anderson Cancer Center
Oncology: Olmutinib (HM61713) for T790M+ NSCLC

3rd Generation EGFR tyrosine kinase inhibitor
via inhibition of activating EGFR mutations & T790M mutations and wild-type EGFR sparing

Key Features

- Irreversible EGFR mutant-specific kinase inhibitor

- Competitive clinical benefits with manageable safety profiles in T790M+ NSCLC patients who previously received EGFR TKI (Phase 2 Study Result)
  - Overall Median PFS: 9.4 months (95% CI 6.9-12.3)
  - Median PFS by brain metastasis at screening:
    - Yes: 8.1 (95% CI 5.6, 10.8) (Log rank p=0.076)
    - No: 11.2 (95% CI 7.2, 15.2)

- Global phase 3 trial to start in 1H 2018 for further assessment of efficacy and safety in T790M+ NSCLC
Next generation anti-PD-1 & anti-PD-L1 immuno-oncology
redirecting immune cells to tumor cells through the cell-cell association

Key Features

- Redirect immune cells to PD-L1+ tumor cells
- Complete blocking of PD-1 & PD-L1 related interactions
- Better efficacy compared to mAb & combination
- Superior efficacy expected against metastatic lesions compared to combination therapy
COLLABORATION
Major R&D Achievements

Collaboration with global partners on various co-development and business opportunities

- **Amosartan**
  - Amlodipine+Losartan
  - The world’s first Combination IMD

- **Efapegrastim**
  - Long acting GCSF analog
  - Co-development & Licensing
  - WW ex. Korea, China, Japan

- **Hyalrheuma**
  - Hyaluronate
  - Development, License & Supply Agreement

- **Hyalrheuma**
  - Development, License & Supply Agreement

- **Rosuzet**
  - Rosuvastatin+Ezetimibe
  - Development, License & Supply Agreement

- **Lilly**
  - HM71224
  - BTK inhibitor
  - Exclusive licensing
  - WW ex. Korea

- **Poziotinib**
  - Pan-HER inhibitor
  - Co-development & Licensing
  - WW ex. Korea, China

- **SANOFI**
  - Efpeglenatide, HM14220
  - LAPS Exd4 Analog, LAPS Insulin Combo
  - Exclusive licensing
  - Worldwide

- **Genentech**
  - HM95573
  - RAF inhibitor
  - Exclusive Licensing
  - WW ex. Korea

- **Hyalrheuma**
  - Development, License & Supply Agreement

- **Poziotinib**
  - Pan-HER inhibitor
  - Co-development & Licensing
  - WW ex. Korea, China

- **HM71224**
  - BTK inhibitor
  - Exclusive licensing
  - WW ex. Korea

- **HM95573**
  - RAF inhibitor
  - Exclusive Licensing
  - WW ex. Korea

- **Collaboration with global partners on various co-development and business opportunities**

- **Oral Platform Tech**
  - Oral paclitaxel/irinotecan
  - Co-development & Licensing

- **SANOFI**
  - Rovelito
  - Irbesartan+Atorvastatin
  - Co-development & Licensing
  - Launched

- **zaiLab.**
  - HM61713
  - 3rd generation EGFR TKI
  - Exclusive licensing
  - China including Hong Kong, Macau

- **Bispecific Antibody**
  - Targeted Immuno-Oncology
  - Collaboration
  - Worldwide
Value-added Programs

- Launching 2~3 products annually in the domestic market
- 6 new products launched in 2017
- Seeking partners for emerging market business
- FDC Product (Rosuzet®, Amosartan®) Collaboration with MSD for 23 countries

<table>
<thead>
<tr>
<th>Product</th>
<th>Launch Year</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monterizine®</td>
<td>Launched 2017</td>
<td>Montelukast + Levocetirizine FDC**</td>
</tr>
<tr>
<td>Rabone D®</td>
<td></td>
<td>Raloxifene + Vild FDC**</td>
</tr>
<tr>
<td>Amosartan Plus®</td>
<td></td>
<td>Amlodipine + Losartan + Chlorothalidone FDC**</td>
</tr>
<tr>
<td>Amosartan Q®</td>
<td></td>
<td>Amlodipine + Losartan + Rosuvastatin FDC**</td>
</tr>
<tr>
<td>Tefovir®</td>
<td></td>
<td>Tenofovir disoproxil phosphate IMD*</td>
</tr>
<tr>
<td>Besigum®</td>
<td></td>
<td>Sofileran tartrate IMD*</td>
</tr>
</tbody>
</table>

- Rosuzet®
  - Rosuvastatin + Ezetimibe FDC**

- Hanmi Tams 0.4mg®
  - Tamsulosin 0.4mg IMD*

- Guguțams®
  - Tamsulosin + Tadalafil FDC**

- Hanmi Flu®
  - Oseltamivir IMD*

- Monterizine®
  - Montelukast + Levocetirizine Chewable FDC**

- IMD*
  - PPI SR
  - Anti-Coagulant

- FDC**
  - HTN & Dyslipidemia
  - Smoking Cessation
  - Osteoporosis

- IMD*
  - Pulmonary arterial HTN

* IMD (Incrementally Modified Drug)
** FDC (Fixed Dose Combination)
Potential news flows in 2018

**PHASE 3**
- *Rolontis™* P3 data read out for neutropenia *(1Q)* & BLA Submission *(4Q)*
- *Olita® (Olmutinib)* Multinational P3 study initiation for NSCLC *(1H)*

**PHASE 2**
- *LAPS GLP/GCG* dual agonist *(HM12525A)* P2 initiation *(1H)*
- *Poziotinib* Global P2 ongoing
- *BTK inhibitor (HM71224)* Global P2 data read out for Rheumatoid Arthritis *(2H)*

**PHASE 1**
- *LAPS Combo (Insulin+GLP-1R)* P1 initiation *(1H)*
- *LAPS Triple Agonist (HM15211)* P1 initiation *(1Q)*
- *LAPS GCG Analog, LAPS GLP-2 Analog* P1 initiation *(1H)*
- *FLT3 Inhibitor* P1 initiation *(1Q)*
Share price recovered
Value creation via progression of R&D pipeline
Thank you